Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced it expects to obtain a secondary listing on the Nasdaq Capital Market by the end of 2024. As announced on 14 February 2023, the Company initiated…
Cyprium Metals Limited (ASX: CYM) (Cyprium or the Company) is pleased to advise that it has entered into a…
Eric Sprott announces that today, 2176423 Ontario Ltd., a corporation which is beneficially owned by him, purchased 770,000 common…
Overview The global regulatory climate around cannabis use is evolving and has resulted in a huge investment opportunity for…
Nova Minerals Limited (Nova or the Company) (ASX: NVA, NASDAQ: NVA, NVAWW OTC: NVAAF, FSE: QM3) is pleased to…
After reaching a 17 year high in January, uranium prices consolidated in Q2, holding above US$82 per pound. Despite…
Google (NASDAQ:GOOGL) parent company Alphabet reported its second quarter results headlined by US$84.74 billion in revenue, showcasing solid growth…
Strategic Resources Inc. (TSXV: SR) (the ‘Company’ or ‘Strategic’) is pleased to announce that it has engaged Societe Generale…
Description The securities of Adisyn Ltd (‘AI1’) will be placed in trading halt at the request of AI1, pending…